EPS for CoreSite Realty (COR) Expected At $1.24; Abeona Therapeutics (ABEO) SI Increased By 1.55%

June 24, 2018 - By Migdalia James

Abeona Therapeutics Inc. (NASDAQ:ABEO) Logo

Abeona Therapeutics Inc (NASDAQ:ABEO) had an increase of 1.55% in short interest. ABEO’s SI was 11.15M shares in June as released by FINRA. Its up 1.55% from 10.98M shares previously. With 904,300 avg volume, 12 days are for Abeona Therapeutics Inc (NASDAQ:ABEO)’s short sellers to cover ABEO’s short positions. The SI to Abeona Therapeutics Inc’s float is 40.03%. The stock increased 3.80% or $0.6 during the last trading session, reaching $16.4. About 699,032 shares traded. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 191.23% since June 24, 2017 and is uptrending. It has outperformed by 178.66% the S&P500. Some Historical ABEO News: 16/03/2018 – ABEONA THERAPEUTICS WITHDRAWS S-1; 11/05/2018 – Abeona Therapeutics Files Shelf Registration for Up to $500M of Securities; 16/03/2018 – ABEONA THERAPEUTICS WITHDRAWS FORM S-1; 15/05/2018 – Castle Hook Partners LP Exits Position in Abeona Therapeutics; 14/05/2018 – Abeona, Audentes Headline Gene & Cell Therapy Meeting This Week; 17/05/2018 – Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting; 23/04/2018 – ABEONA REPORTS FDA GRANTS RMAT DESIGNATION TO ABO-102 GENE; 15/03/2018 – ABEONA THERAPEUTICS – FDA GRANTED RARE PEDIATRIC DISEASE DESIGNATION FOR ABO-202 PROGRAM, AN AAV-BASED GENE THERAPY FOR TREATMENT OF CLN1 DISEASE; 18/05/2018 – ABEONA THERAPEUTICS- RESULTS FROM PHASE 1/2 CLINICAL TRIAL FOR ABO-102 SHOW DURABLE BIOPHYSICAL REDUCTIONS OF DISEASE BURDEN; 31/05/2018 – Abeona Therapeutics Announces Opening of Commercial Gene & Cell Therapy Manufacturing Facility in Ohio

Analysts expect CoreSite Realty Corporation (NYSE:COR) to report $1.24 EPS on July, 26.They anticipate $0.14 EPS change or 12.73% from last quarter’s $1.1 EPS. COR’s profit would be $59.88 million giving it 22.00 P/E if the $1.24 EPS is correct. After having $1.27 EPS previously, CoreSite Realty Corporation’s analysts see -2.36% EPS growth. The stock decreased 1.25% or $1.38 during the last trading session, reaching $109.12. About 369,512 shares traded or 16.21% up from the average. CoreSite Realty Corporation (NYSE:COR) has risen 0.94% since June 24, 2017 and is uptrending. It has underperformed by 11.63% the S&P500. Some Historical COR News: 07/03/2018 CoreSite Announces Availability of VMware Cloud on AWS in Four Markets; 20/04/2018 – CORESITE REALTY CORP – AMENDMENT AND EXPANSION INCREASES REVOLVING CREDIT FACILITY BY AN INCREMENTAL $100 MLN OF BORROWING CAPACITY, TO $450 MLN; 24/05/2018 – CORESITE REALTY CORP COR.N SETS QUARTERLY DIVIDEND OF $1.03/SHR; 30/03/2018 – Factors of Influence in 2018, Key Indicators and Opportunity within Hillenbrand, Synnex, CoreSite Realty, Orchids Paper Product; 24/04/2018 – Nuveen Global Infrastructure Adds CoreSite Realty; 20/04/2018 – CORESITE REALTY CORP – AMENDMENT AND EXPANSION EXTENDS PRIMARY TERM OF FACILITY TO APRIL 2022, WITH A ONE-YEAR EXTENSION OPTION; 20/04/2018 – CoreSite Announces Amended and Expanded Credit Facility Increasing Total Borrowing Capacity to $1.05B; 26/04/2018 – CoreSite Realty 1Q Rev $129.6M; 26/04/2018 – CoreSite Realty Sees FY FFO $4.92/Shr-FFO $5.04/Shr; 24/05/2018 – CoreSite Realty Raises Dividend to $1.03

More notable recent Abeona Therapeutics Inc. (NASDAQ:ABEO) news were published by: Seekingalpha.com which released: “Abeona Therapeutics: What The Latest Data For ABO-102 Foretells?” on May 29, 2018, also Fool.com with their article: “3 Small-Cap Biotech Stocks to Keep on Your Radar” published on June 20, 2018, Businesswire.com published: “Newman Ferrara LLP Announces Corporate Governance Investigation of Abeona Therapeutics Inc. – ABEO” on June 18, 2018. More interesting news about Abeona Therapeutics Inc. (NASDAQ:ABEO) were released by: Crainscleveland.com and their article: “Abeona Therapeutics opens The Elisa Linton Center for Rare Disease Therapies” published on June 11, 2018 as well as Prnewswire.com‘s news article titled: “Cancer Treatment Breakthroughs Providing Boost for Biotech Market” with publication date: June 06, 2018.

Among 11 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics had 48 analyst reports since December 16, 2015 according to SRatingsIntel. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) has “Buy” rating given on Monday, January 29 by Cantor Fitzgerald. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) has “Buy” rating given on Tuesday, June 5 by H.C. Wainwright. On Thursday, February 1 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm has “Buy” rating given on Monday, October 9 by H.C. Wainwright. The firm has “Buy” rating by Cantor Fitzgerald given on Monday, September 25. On Thursday, April 12 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm earned “Buy” rating on Tuesday, July 18 by Maxim Group. On Friday, January 6 the stock rating was initiated by Jefferies with “Buy”. The rating was maintained by H.C. Wainwright on Friday, September 8 with “Buy”. Rodman & Renshaw reinitiated the shares of ABEO in report on Wednesday, April 20 with “Buy” rating.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $775.81 million. The companyÂ’s lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

Investors sentiment decreased to 1.1 in Q1 2018. Its down 0.16, from 1.26 in 2017Q4. It dived, as 42 investors sold CoreSite Realty Corporation shares while 92 reduced holdings. 54 funds opened positions while 94 raised stakes. 32.58 million shares or 1.04% less from 32.92 million shares in 2017Q4 were reported. New York State Common Retirement Fund has 82,378 shares. Adelante Capital Mngmt Lc stated it has 0.07% of its portfolio in CoreSite Realty Corporation (NYSE:COR). Goldman Sachs Gp Inc holds 211,790 shares or 0.01% of its portfolio. American State Bank holds 0.14% in CoreSite Realty Corporation (NYSE:COR) or 4,723 shares. Geode Capital Management Limited has invested 0.01% in CoreSite Realty Corporation (NYSE:COR). Employees Retirement Association Of Colorado invested in 0.11% or 165,980 shares. Rhumbline Advisers holds 78,321 shares. Stratos Wealth Prns Ltd has invested 0.02% in CoreSite Realty Corporation (NYSE:COR). Utd Ser Automobile Association reported 6,322 shares stake. The New Jersey-based Nj State Employees Deferred Compensation Plan has invested 0.07% in CoreSite Realty Corporation (NYSE:COR). State Treasurer State Of Michigan, a Michigan-based fund reported 12,500 shares. Amalgamated Bank invested in 0.02% or 7,590 shares. Glob Endowment Management Limited Partnership owns 13,090 shares or 0.19% of their US portfolio. Eagle Asset Mngmt invested in 67,674 shares or 0.04% of the stock. Macquarie Group Limited reported 0% of its portfolio in CoreSite Realty Corporation (NYSE:COR).

CoreSite Realty Corporation delivers secure, reliable, high-performance data center and interconnection solutions to a growing customer ecosystem across eight key North American markets. The company has market cap of $5.27 billion. More than 1,200 of the world??s leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. It has a 55.96 P/E ratio. Our scalable, flexible solutions and 430+ dedicated employees consistently deliver unmatched data center options ?? all of which leads to a best-in-class customer experience and lasting relationships.

Among 21 analysts covering CoreSite Realty (NYSE:COR), 13 have Buy rating, 0 Sell and 8 Hold. Therefore 62% are positive. CoreSite Realty had 63 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of CoreSite Realty Corporation (NYSE:COR) earned “Buy” rating by Robert W. Baird on Friday, March 9. The firm has “Buy” rating given on Tuesday, December 19 by Robert W. Baird. Credit Suisse maintained the shares of COR in report on Friday, April 27 with “Neutral” rating. As per Thursday, October 12, the company rating was maintained by KeyBanc Capital Markets. The rating was maintained by SunTrust on Thursday, October 12 with “Buy”. The rating was maintained by RBC Capital Markets with “Buy” on Thursday, June 8. RBC Capital Markets maintained CoreSite Realty Corporation (NYSE:COR) rating on Sunday, February 11. RBC Capital Markets has “Buy” rating and $113.0 target. The firm has “Outperform” rating by RBC Capital Markets given on Tuesday, February 16. The rating was maintained by Jefferies on Friday, September 15 with “Buy”. The firm earned “Buy” rating on Monday, October 23 by Jefferies.

Another recent and important CoreSite Realty Corporation (NYSE:COR) news was published by Seekingalpha.com which published an article titled: “AT&T Is A Buy – Cramer’s Lightning Round (6/6/18)” on June 07, 2018.

CoreSite Realty Corporation (NYSE:COR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Migdalia James

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: